

Request for Prior Authorization Olezarsen (Tryngolza)

FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #					Patient name						DOB										
					. 5																
Pa	tient add	lress																			
Provider NPI Prescriber name										Phone											
														F							
Prescriber address														Fax							
Pharmacy name						Address						Phone									
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.																					
Pharmacy NPI				Pharmacy fax NDC																	
Prior authorization (PA) is required for olezarsen (Tryngolza). Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agent(s) would be medically contraindicated. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following criteria are met:																					
1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and																					
2. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) confirmed by genetic testing, (e.g., biallelic pathogenic variants in FCS-causing genes [LPL, GPIHBP1, APOA5, APOC2, or LMF1]) (attach genetic testing results); and																					
3. The patient has a current fasting triglyceride level of $880 mg/dL$ or greater (attach current lipid panel obtained within the past $30 days$); and																					
4. The patient will use medication in combination with a low-fat diet (≤ 20 grams of total fat per day); and																					
5. Is prescribed by or in consultation with a cardiologist, an endocrinologist, or a provider who specializes in lipid management.																					
If the criteria for coverage are met, initial requests will be given for 6 months. Requests for continuation of therapy will be considered at 12-month intervals under the following conditions:																					
1.	 Documentation of a decrease in fasting triglyceride level from baseline (attach current lipid panel obtained within the past 30 days); and 										the										
2.	Patient continues to use medication in combination with a low-fat diet (≤ 20 grams of total fat per day); and																				
3.	 Is prescribed by or in consultation with a cardiologist, an endocrinologist, or a provider who specializes in lipid management. 																				
No	n-Pref	erred																			
	Tryngo	olza																			
	;	Strengtl	h			Usage Inst	ructions		Qu	anti	ity			Da	y's S	uppl	y				
iad	nosis (attach o	nenet	ic te	etin	a results):						_	_								

Request for Prior Authorization Olezarsen (Tryngolza) (PLEASE PRINT – ACCURACY IS IMPORTANT)

Current Fasting triglyceride level:							
Date obtained (attach current lipid panel obtained within the past 30 days):							
Will patient use medication in combination with a low-fat diet (≤ 20 gra ☐ Yes ☐ No	ams of total fat per day)?						
Is prescriber a cardiologist, an endocrinologist, or a provider who spe	ecializes in lipid management?						
□ Yes, document specialty:							
■ No If no, note consultation with specialist:							
Consultation Date:Physician Name, Specialty & Phone:							
Renewal Requests							
Document a decrease in fasting triglyceride level from baseline (at	tach current lipid panel obtained						
within the past 30 days).							
Current fasting triglyceride level: Date obtained	Date obtained:						
Is patient continuing to use medication in combination with a low-fat oday)?	diet (≤ 20 grams of total fat per						
☐ Yes ☐ No							
Is prescriber a cardiologist, an endocrinologist, or a provider who spe	ecializes in lipid management?						
☐ Yes, document specialty:							
■ No If no, note consultation with specialist: Consultation Date:Physician Name, Specialty & Phone:							
Medical or contraindication reason to override trial requirements:							
Attach lab results and other documentation as necessary.							
	Date of submission						

IMPORTANT NOTE: In evaluating requests for prior authorization, the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary, by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

Page 2 of 2 470-0196 (10/25)